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Abstract
Background and Purpose—Unrecognized or unreported stroke-like symptoms, called covert
symptoms, occur in persons free of clinical stroke. Whether covert symptoms are associated with
subclinical brain infarcts (SBI) is unknown. This study examined the association between covert
stroke-like symptoms and SBI/stroke in persons with no history of stroke or TIA.
Methods—1881 Atherosclerosis Risk in Communities (ARIC) participants free of clinical stroke
or transient ischemic attack (TIA) (40% male, 50% African-American, 47–70y) were queried for
covert symptoms and underwent cerebral MRI during baseline MRI visit. Symptoms were
reassessed after 3 years at Visit 4 (n=1001; 39% male, 50% African-American), and
approximately 10 years with a follow-up MRI (n=1006; 40% male, 50% African-American, 61–
83y).
Results—Covert symptoms were associated with prevalent SBI (OR=1.94, [95% CI 1.21, 3.11],
p=0.006). Baseline MRI visit symptoms were not associated with SBI at follow-up MRI visit. In
participants without SBI at baseline, symptoms at Visit 4(OR=2.96, [1.23, 7.13], p=0.016) and
symptoms at follow-up MRI visit (OR=4.29, [2.51, 7.33], p<0.001) were associated with a
combined outcome of new SBI on follow-up MRI/clinical stroke. Covert symptoms at follow-up
MRI visit were also associated with having new SBI (OR=2.26, (1.18, 4.32), p=0.014) on the
follow-up MRI that were not seen on the baseline MRI.
Conclusions—Covert neurological symptoms were associated with prevalent SBI, and when
ascertained at time of follow-up MRI, with new SBI. Covert symptoms may reflect heightened
risk for future infarcts.
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Stroke-like neurologic symptoms are not uncommon in persons free of a clinical history of
stroke and transient ischemic attacks (TIA) and thus may be considered “covert.” In the
Atherosclerosis Risk in Communities (ARIC) study, 6% of participants without a history of
stroke or TIA reported symptoms at baseline evaluation1, as did 17.8% in the Reasons for
Geographic and Racial Differences in Stroke (REGARDS) Study.2 In both studies,
symptoms, which we hereafter refer to as “covert” symptoms, have been associated with
cerebrovascular risk factors3,4 and increased risk of incident clinical stroke.5,6 These
associations may be explained by subclinical cerebrovascular disease. However, this is not
known since the relationship between symptoms and signs of subclinical disease on brain
imaging has not been reported.
Neurological symptoms in persons with no history of clinical stroke could be due to silent or
subclinical brain infarcts (SBI) that represent occult cerebrovascular disease from chronic
ischemic processes or hypoperfusion.7 SBI are common, increase with age, and are
associated with incident stroke, dementia, cognitive decline,8–12 and falls.13 This study
examined the association of covert neurological symptoms with SBI or a combined outcome
of SBI or clinical stroke on follow-up visits in ARIC participants free of clinical stroke or
TIA at the baseline MRI visit. Symptoms indicative of increased risk of subclinical
cerebrovascular disease could provide a simple, clinical risk stratification tool for
identifying individuals for whom imaging and preventive therapy may be warranted.
Methods
ARIC, a longitudinal study of cardiovascular diseases, enrolled a probability sample cohort
of 15,792 men and women (45–64 yrs) at four US sites: Forsyth County, North Carolina;
Jackson, Mississippi (African-Americans only); Minneapolis, Minnesota; and Washington
County, Maryland. Eligible participants underwent baseline clinical examination in 1987–
1989 and subsequent triennial visits through 1998, as previously described.14 The current
study uses data from visit 3 (1993–95), hereafter called the baseline MRI visit; visit 4
(1996–98), and an ancillary study visit (2004–2006), hereafter called the follow-up MRI
visit. Since the MRI was only conducted at Forsyth County and Jackson as previously
described,15 this analysis is limited to participants at these sites. Institutional review boards
approved study protocols; all participants provided informed consent.
Of 2887 participants ≥55 years at the Forsyth County and Jackson sites, 1881 had MRI and
symptoms questionnaire data at baseline. Usual safety exclusion criteria for MRI excluded
2% of women and 6% of men. Of the 1881 at baseline MRI visit, 1001 had visit 4 data; 1006
had follow-up MRI visit data, including the symptoms questionnaire, physical examination,
and repeat MRI. Figure 1 shows study flow and related prevalence vs. incidence analytic
frameworks.
The TIA/Stroke Symptoms Questionnaire, used in nearly identical fashion in the
Asymptomatic Carotid Atherosclerosis Study clinical trial and validated against
neurologists’ ascertainment,16 was administered at each visit by certified interviewers.
Participants were asked if a physician had ever told them that they have had a stroke or TIA.
They subsequently were asked whether they had experienced a sudden episode of any of six
neurologic trigger symptoms since the previous ARIC visit: 1) speech dysfunction; 2) loss of
vision; 3) double vision; 4) weakness or paralysis; 5) numbness or tingling; or 6) dizziness
or loss of balance. For endorsed symptoms, additional questions explored occurrence, mode
of onset, duration, frequency, nature, and concomitant symptoms to exclude non-
cerebrovascular symptoms. The algorithm defining stroke-like symptoms has been
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previously described and validated using an ARIC study clinician’s diagnosis based on the
clinician’s review of symptoms and evaluation of participants.1 Participants were asked if
they sought medical attention and, if so, what diagnosis was given. Comparisons were made
between the algorithm, ARIC study clinician, and the participant’s reported diagnosis if
available. Only symptoms of sudden onset lasting ≥30 seconds and determined to be of
cerebrovascular origin were considered positive. Covert symptoms were defined as
symptomatic on the TIA/Stroke Symptoms Questionnaire in persons free of clinical TIA/
stroke.
Clinical stroke was defined using cohort examinations, annual follow-up interviews, and
community surveillance, including medical record reviews of potential stroke cases as
previously described.17 Potential cases were reviewed separately using a computerized
algorithm and a physician reviewer. Both drew upon data from radiologic tests, lumbar
puncture, hospital discharge summaries, autopsy findings, other clinical information, and
medical records to evaluate neurological deficits. Final classification was established when
the computer algorithm and reviewer agreed or when a second physician reviewer resolved
discordant classification.
ARIC cerebral MRI protocols were identical to those in the Cardiovascular Health
Study.15, 18 Briefly, 1.5T magnetic resonance scanners (GE and Picker) were used to obtain
5mm axial MR images angled parallel to the anterior commissure-posterior commissure
line. Although interval MRI scanner upgrades occurred between visits, follow-up scans were
matched as closely as possible to baseline visit reference levels for signal-to-noise ratio,
resolution, and contrast-weighting. The resulting digitized images, evaluated at the ARIC
MRI Reading Center by certified neuroradiologists, were subject to routine quality control
checks. Methods for scoring scans were identical at both visits; new readers were tested on a
sample of earlier scans to ensure continuity.
MR images obtained at the two visits were read independently, and each image was read by
two neuroradiologists, with discrepant infarct findings subject to adjudication. Lesions 3mm
in size and visible on both T1- and proton-density/T2-weighted images were classified as
infarcts. In the basal ganglia or cortical gray matter, lesions were considered infarcts
regardless of T1-weighted image intensity.
The primary outcome, SBI, was defined as infarcts on MRI in persons free of clinical stroke
or TIA at the same or a prior visit. Participants with prevalent clinical stroke at baseline MRI
visit were excluded. Prevalent SBI at baseline MRI visit was defined as an infarct on
baseline MRI. Prevalent SBI at the follow-up MRI was defined as an infarct on the follow-
up MRI among those without clinical stroke at or prior to the follow-up MRI visit. Incident
SBI was defined as an infarct on follow-up MRI and no visible infarcts on baseline MRI in
persons free of clinical stroke at any visit. The combined outcome incident SBI/stroke
included anyone with incident SBI at follow-up MRI or who had experienced clinical stroke
after baseline MRI visit. Figure 1 shows data flow for these definitions.
Hypertension was defined by self-report, taking anti-hypertensive medication, or blood
pressure ≥140/90. Diabetes was defined by self-report, taking medications for diabetes, or
having fasting glucose ≥140 mg/dl except at follow-up MRI visit, when only self-report was
available. Smoking status was categorized as never, former, or current smoker. These
covariates were chosen based on the Framingham Stroke Risk Factors (FSRF) with minimal
modifications. SBP and medication use were included in the definition of hypertension. We
chose not to use other FSRF due to reductions in the sample size, low prevalence, and the
fact that analyses using FSRF in the smaller sample showed similar but stronger
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associations. Therefore, the associations reported are conservative (data not shown; results
available from corresponding author).
Statistical Analysis
Univariate comparisons were conducted using t-tests for continuous data and chi-square
tests for categorical data. Concurrent (same visit) associations between symptoms and
prevalent outcomes were estimated using marginal multilevel logistic regression models fit
with generalized estimating equations19 to account for within-subject associations. Robust
variance estimates are reported.
Prevalence Analyses—Potential differences in relationships between prevalent SBI and
symptoms across visits were examined using interaction terms between symptom and visit
variables in sensitivity analyses (http://stroke.ahajournals.org, Table S1). Associations
between symptoms and SBI at the same visit were examined. Prevalence analyses were
pooled since no substantial time-by-visit effect modifications were found.
Incidence Analyses—Associations between symptoms and incident SBI or combined
incident SBI/Stroke outcomes were estimated using logistic regression.
All multivariate regression models included terms for age, sex, BMI, education,
hypertension, diabetes, smoking, and a three-level race-site variable (African-American—
Forsyth; African-American—Jackson; White—Forsyth). This race-site variable was used to
account for both race and site effects while avoiding the zero cell issue, since the Jackson
cohort was entirely African-American. Sensitivity analyses were conducted to examine
effects of missingness using weighted GEE techniques20; nearly identical results were
obtained.
Results
Participants without clinical stroke at baseline MRI (n=1881; mean age 63y; 40% men; 50%
African-American, of whom 88% were from Jackson site) were followed for an average of
10.5 years. Most (65%) were <65 years at baseline, i.e. mid-life; 98% were >65 years at the
follow-up MRI visit. Table 1 shows participant characteristics at each visit, stratified at
baseline and follow-up MRI visits by presence/absence of SBI. Associations with SBI at
baseline MRI visit included age, systolic and diastolic blood pressure, black race, diabetes,
hypertension, and education. Only age, systolic blood pressure, and hypertension were
statistically associated with SBI at follow-up MRI. Comparison of baseline characteristics
for those with and without the repeat MRI (http://stroke.ahajournals.org, Table S2) showed
that participants who did not return were slightly older, had higher systolic blood pressure,
BMI, and higher prevalence of hypertension, diabetes and smoking. Most differences were
of questionable clinical significance.
Symptoms were infrequent at all visits (2.9% at baseline, 2.4% at Visit 4, and 5.1% at
follow-up MRI; Table 1), but were highly associated with SBI. Figure 2 shows the
prevalence of SBI increased with age in both those with and without covert symptoms.
However, at any age, SBI prevalence was higher among those with symptoms than without
(e.g. among 80yo persons, 54% of those with symptoms would be expected to have SBI
versus 36% without symptoms). As shown in Table 2, a nearly two-fold risk of concurrent,
prevalent SBI was observed (adjusted OR=1.94; 95% CI 1.21, 3.11) for participants
reporting any symptom versus no symptoms. Associations were similar at both MRI visits,
with no significant symptoms-visit interaction (http://stroke.ahajournals.org, Table S1).
Interaction terms between symptoms and age, hypertension, diabetes, sex and race-site in
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separate models did not suggest a differential relationship between symptoms and SBI by
these subgroups, although power to detect differences was limited.
Neither baseline nor Visit 4 symptoms were associated with incident SBI at follow-up MRI;
however, symptoms at the follow-up MRI were associated with double the risk of incident
SBI on the follow-up MRI (OR=2.26, 95% CI 1.18, 4.32; Table 3). Additionally, we
considered whether persons with covert symptoms at prior visits could have developed
interim clinical stroke. Their exclusion from analyses would underestimate potential
associations. We therefore created an incident cerebrovascular disease outcome by
combining incident SBI or clinical stroke (31 with stroke, 172 with incident SBI). Baseline
symptoms (reported an average 10.5 years prior to follow-up MRI) were not associated with
the incident SBI/stroke outcome (OR=0.69, 95% CI 0.23, 2.09). However, visit 4 symptoms
(reported an average 7.5 years prior to follow-up MRI), were associated with a nearly three-
fold greater risk of incident SBI/stroke outcome (OR=2.96, 95% CI 1.23, 7.13). Concurrent
symptoms at the follow-up MRI were associated with a more than four times greater risk of
incident SBI/stroke outcome (OR=4.29, 95% CI 2.51, 7.33).
Discussion
This study demonstrated that covert stroke-like symptoms assessed at older ages at the time
of the follow-up MRI were associated with new SBI compared to the baseline MRI. Remote
(nearly eight years prior) covert stroke-like symptoms were also associated with a combined
outcome of clinical stroke/new SBI on a follow-up MRI. The several-year lag between
symptoms and outcomes potentially present an important opportunity to implement
preventive measures to reduce risk of stroke. Our findings build on those of the recent
REGARDS study6 and earlier ARIC findings5 of the association between symptoms and
stroke by demonstrating associations between symptoms and subclinical disease. This
suggests that subclinical disease may cause “whispering” symptoms21 of cerebrovascular
disease that are not routinely detected.
Both ARIC and REGARDS have shown associations between covert symptoms and stroke
risk factors3,4 as well as clinical stroke.5,6 The current study fills a salient gap in knowledge
regarding the association between symptoms and clinical disease in two ways. First,
symptoms reported in ARIC underwent additional scrutiny before being classified as
“stroke-like” which should reduce misclassification of non-cerebrovascular symptoms. This
may explain the lower prevalence of symptoms in ARIC compared to the REGARDS study.
Second, we report associations between symptoms and subclinical disease, which supports
findings from ARIC and REGARDS linking covert symptoms to clinical disease in two
populations free of clinical TIA/stroke at the time of symptoms ascertainment. Importantly,
these findings provide evidence for a hypothesized pathway whereby seemingly subclinical
cerebrovascular disease is visible on imaging and causes symptoms that can be elicited with
directed questioning but do not seem to result in a clinical diagnosis of TIA or stroke in the
community. The subclinical disease may subsequently contribute to future stroke risk.
Therefore, identifying symptoms that alert clinicians to subclinical disease may present an
opportunity for stroke prevention. The findings from REGARDS and ARIC are congruent,
and suggest that these symptoms warrant further study as important risk factors in predicting
and preventing disease.
More remote symptoms, i.e. on average 10.5 years earlier, in primarily middle-aged
participants were not associated with future clinical or subclinical cerebrovascular disease
assessed in late life. Some explanations could be more false positives in a younger
population with lower probability of disease, or the possibility that participants with
symptoms sought treatment in the inter-visit interval.
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Surprisingly, many participants who reported symptoms at earlier visits did not report them
at future visits (http://stroke.ahajournals.org, Table S3). Several explanations are possible:
participants may not have recalled subtle, transient symptoms over the long inter-visit
intervals and were misclassified as having no symptoms; symptomatic patients may have
sought treatment that led to symptom resolution; participants may have developed overt
symptoms that resulted in a diagnosis of TIA/stroke, thus eliminating them from analyses of
incident subclinical disease. To examine the latter consideration, we evaluated 29
participants who developed incident stroke by the follow-up MRI visit. Of these, 14%
reported symptoms at the previous visit compared to 2% without stroke. Thus, inquiring
about symptoms closer to the time of the repeat MRI might reveal associations between
symptoms and incident disease. Indeed, concurrent reporting of symptoms at the follow-up
MRI was associated with a doubled risk of incident SBI, even though the symptoms being
recalled had occurred over the prior eight years.
Low prevalence of symptoms and clinical stroke limited this study’s statistical power for
evaluating some associations, such as relationships between individual symptoms and
outcomes. Another limitation involves race-specific analyses. All participants at the Jackson,
Mississippi site are African-American, and this site accounted for nearly 90% of all African-
Americans in the study. Thus, observed differences may be due to race, regional differences,
or other factors. We accounted for this by including a three-level race-site covariate (AA-
Jackson, AA-Forsyth, White-Forsyth) instead of separate race and sex adjustors that would
have extrapolated estimates to a nonexistent White-Jackson group. We believe our findings
are robust given associations between symptoms and clinical stroke in REGARDS6 which
also sampled blacks and whites in the south and southeastern United States.
The ARIC algorithm incorporates clinical interpretation to distinguish cerebrovascular from
non-cerebrovascular symptoms, thereby providing comparability to clinical observations.
Further clinical review of covert neurological symptoms similar to those assessed by the
ARIC algorithm might help distinguish markers of cerebrovascular disease useful for
identifying potentially high-risk individuals who warrant further evaluation and/or
treatment.
Summary
Covert neurological symptoms in participants without a history of stroke or TIA are
associated with increased risk for prevalent SBI and incidence of SBI and clinical stroke.
These symptoms may be assessed in systematic screening to identify individuals at greater
risk for stroke. Clinical trials are needed to evaluate whether preventive treatment, such as
medication or education with modification of risk factors, is cost-effective or improves
outcomes.
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Adjusted prevalence of SBI by symptom status across age
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Table 2
Associations between symptoms and SBI at the same visit (prevalence analyses).
Symptoms Odds Ratio p Value 95% Confidence Interval
Unadjusted
 ≥ 1 Symptom 2.39 0.001 (1.56, 3.66)
 Speech problem 3.99 0.002 (1.67, 9.51)
 Vision problem 2.13 0.018 (1.14, 4.00)
 Double vision 1.75 0.40 (0.47, 6.50)
 Paralysis 5.27 0.02 (1.31, 21.19)
 Dizziness 1.75 0.40 (0.47, 6.50)
 Numbness 2.10 0.13 (0.81, 5.46)
Adjusted
 ≥ 1 Symptom 1.94 0.006 (1.21, 3.11)
 Speech problem 3.46 0.013 (1.30, 9.20)
 Vision problem 1.66 0.16 (0.82, 3.35)
 Double vision 0.96 0.99 (0.23, 4.18)
 Paralysis 3.12 0.07 (0.93, 10.44)
 Dizziness 2.12 0.27 (0.56, 7.99)
 Numbness 1.59 0.33 (0.62, 4.04)
Adjusted for age, sex, race-site, BMI, education, hypertension, diabetes, smoking. Estimates are from longitudinal models pooling information on
within-visit associations.
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